ArticleJournal for immunotherapy of cancer2018
RAS status and neoadjuvant chemotherapy impact CD8+ cells and tumor HLA class I expression in liver metastatic colorectal cancer.
Article in Journal for immunotherapy of cancer, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 3 syntheses or guidelines pooled it, 39 citations in OpenAlex.
- Neoadjuvant chemoradiotherapy with or without PD-1/PD-L1 inhibitors in locally advanced rectal cancer: a systematic review and meta-analysis.BMC cancer · 2025Pooled it
- The Efficacy and Safety of Durvalumab and Tremelimumab with Concomitant Treatment for MSS/pMMR Metastatic Colorectal Cancer: A Single Arm Meta-Analysis.Journal of gastrointestinal cancer · 2025Pooled it
- Cancer-associated fibroblasts and their prognostic role in colorectal cancer: review and meta-analysis.Frontiers in oncology · 2025Pooled it
- First-line durvalumab and tremelimumab with chemotherapy in RAS-mutated metastatic colorectal cancer: a phase 1b/2 trial.Nature medicine · 2023Trial
- First-line durvalumab and tremelimumab with chemotherapy in RAS-mutated metastatic colorectal cancer: a phase 1b/2 trial.Nature medicine · 2023Trial
- Immune microenvironment in patients with mismatch-repair-proficient oligometastatic colorectal cancer exposed to chemotherapy: the randomized MIROX GERCOR cohort study.Molecular oncology · 2022Trial
- Neoadjuvant chemotherapy is associated with a transient increase of intratumoral T-cell density in microsatellite stable colorectal liver metastases.Cancer biology & therapy · 2020Trial
- Pooled analysis of 2 clinical trials of first-line chemoimmunotherapy for metastatic microsatellite stable colorectal cancer MEDITREME and METIMMOX studies.Oncoimmunology · 2026Article
- Article
- Cathepsin-D-mediated MHC class I degradation contributes to immune evasion in colorectal cancer.Cell reports. Medicine · 2026Article
- Independent risk and protective factors for oxaliplatin-induced hypersensitivity reactions: a retrospective study.Frontiers in pharmacology · 2025Article
- Neoadjuvant immunotherapy for colorectal cancer: Right regimens, right patients, right directions?Frontiers in immunology · 2023Review
- The immune modifying effects of chemotherapy and advances in chemo-immunotherapy.Pharmacology & therapeutics · 2022Review
- Identification of Genes Related to 5-Fluorouracil Based Chemotherapy for Colorectal Cancer.Frontiers in immunology · 2022Article
- The effect of neoadjuvant chemotherapy on the tumor immune microenvironment in gastrointestinal tumors.Frontiers in oncology · 2022Review
- Biglycan as a potential regulator of tumorgenicity and immunogenicity in K-RAS-transformed cells.Oncoimmunology · 2022Article
- Tumour immune microenvironment biomarkers predicting cytotoxic chemotherapy efficacy in colorectal cancer.Journal of clinical pathology · 2021Review
- Whole exome and transcriptome sequencing reveal clonal evolution and exhibit immune-related features in metastatic colorectal tumors.Cell death discovery · 2021Article
- HLA class I loss in colorectal cancer: implications for immune escape and immunotherapy.Cellular & molecular immunology · 2021Review
- QuPath Digital Immunohistochemical Analysis of Placental Tissue.Journal of pathology informatics · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundT lymphocytes and HLA expression on tumor cell both influence prognostic of localized colorectal cancer, but their role following chemotherapy in patients with liver metastatic colorectal cancer (mCRC) was not addressed.
methodsOne hundred fourteen patients treated in curative intend of liver mCRC were included in this retrospective study. Patients were either untreated or treated with neoadjuvant therapy containing an anti-EGFR, bevacizumab or oxaliplatin. Immune densities were quantified in the tumor core and in invasive margin of metastases, using Qupath software or a pathologist's quantification. CD8, NKp46, Foxp3, CD163, HLA, PD-L1 were analyzed and were correlated with progression free survival (PFS) and overall survival (OS) using multivariable Cox proportional hazards models.
resultsIn the whole cohort only a high CD8+ cells infiltrate, a high HLA-I expression and wild-type RAS/RAF status were associated with a better overall survival in both univariate and multivariate model. Moreover, CD8+ cells immune infiltrate at invasive margin combined to HLA expression in cancer cell could increase patient's outcome prediction. RAS status but not immune cell infiltrate was associated with HLA expression on tumor cells. In comparison to untreated patients, neoadjuvant chemotherapy induced CD8+ cells recruitment and increased PD-L1 staining in immune infiltrates only for WT RAS patients. In this context, anti-EGFR and oxaliplatin based chemotherapy are the most powerful to induce CD8+ cells mobilization within the metastatic site.
conclusionsWhile CD8 infiltrate and HLA expression appear to be prognostic for mCRC, CD8 and PD-L1 infiltrate are enhanced by neoadjuvant chemotherapy in mCRC under RAS status dependence.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.